Acurox NDA Returns To FDA Without Niacin, But With More Dosing Flexibility
This article was originally published in The Pink Sheet Daily
Executive Summary
King and Acura are refiling the abuse-resistant oxycodone, this time without the addition of vitamin B3 that FDA and an advisory panel said would do no good at stopping abuse.
You may also be interested in...
Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out
FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.
King Aims To File New Acurox NDA In Early 2011
King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5
Acurox Drops Niacin, But King And Acura Need New Study For Reformulation
Firms will submit NDA for a revised version of their oxycodone formulation Acurox that offers impediments to abuse by snorting or injection but does not contain niacin, which FDA says is ineffective at preventing oral abuse.